Heidelberg Pharma (XTRA:HPHA) - Share price, News & Analysis

HPHA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

HPHA Stock Overview

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally.

Rewards

Revenue is forecast to grow 18.31% per year

Risk Analysis

Earnings are forecast to decline by an average of 0.5% per year for the next 3 years

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months

Negative shareholders equity

+ 3 more risks

Heidelberg Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Heidelberg Pharma
Historical stock prices
Current Share Price	€5.00
52 Week High	€8.68
52 Week Low	€3.41
Beta	-0.73
1 Month Change	-5.66%
3 Month Change	24.84%
1 Year Change	-21.51%
3 Year Change	84.50%
5 Year Change	68.78%
Change since IPO	-90.54%

Shareholder Returns

	HPHA	DE Biotechs	DE Market
7D	0.8%	4.3%	-0.09%
1Y	-21.5%	-31.4%	-12.9%

Return vs Industry: HPHA exceeded the German Biotechs industry which returned -31.4% over the past year.

Return vs Market: HPHA underperformed the German Market which returned -12.9% over the past year.

Price Volatility

Is HPHA's price volatile compared to industry and market?
HPHA volatility
HPHA Average Weekly Movement	17.6%
Biotechs Industry Average Movement	8.1%
Market Average Movement	6.4%
10% most volatile stocks in DE Market	10.6%
10% least volatile stocks in DE Market	3.5%

Stable Share Price: HPHA is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: HPHA's weekly volatility has increased from 10% to 18% over the past year.

About the Company

Founded	Employees	CEO	Website
1997	89	Jan Schmidt-Brand	https://heidelberg-pharma.com

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors.

Heidelberg Pharma Fundamentals Summary

How do Heidelberg Pharma's earnings and revenue compare to its market cap?
HPHA fundamental statistics
Market Cap	€170.88m
Earnings (TTM)	-€27.06m
Revenue (TTM)	€2.40m

71.2x

P/S Ratio

-6.3x

P/E Ratio

Is HPHA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
HPHA income statement (TTM)
Revenue	€2.40m
Cost of Revenue	€4.27m
Gross Profit	-€1.87m
Other Expenses	€25.20m
Earnings	-€27.06m

Last Reported Earnings

Feb 28, 2022

Next Earnings Date

Jul 12, 2022

Earnings per share (EPS)	-0.79
Gross Margin	-77.69%
Net Profit Margin	-1,127.16%
Debt/Equity Ratio	-4,143.8%

How did HPHA perform over the long term?

See historical performance and comparison

Valuation

Is Heidelberg Pharma undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

In this section, we usually try to help investors determine whether Heidelberg Pharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Heidelberg Pharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.

Future Growth

How is Heidelberg Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-0.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HPHA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HPHA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HPHA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HPHA's revenue (18.3% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: HPHA's revenue (18.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if HPHA's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Heidelberg Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-23.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: HPHA is currently unprofitable.

Growing Profit Margin: HPHA is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: HPHA is unprofitable, and losses have increased over the past 5 years at a rate of 23.9% per year.

Accelerating Growth: Unable to compare HPHA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HPHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: HPHA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Financial Health

How is Heidelberg Pharma's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: HPHA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: HPHA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.

Debt to Equity History and Analysis

Debt Level: HPHA has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: HPHA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HPHA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: HPHA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26.5% each year

Dividend

What is Heidelberg Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate HPHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HPHA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HPHA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HPHA's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as HPHA has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure

CEO

Jan Schmidt-Brand (63 yo)

9.67yrs

Tenure

€474,360

Compensation

Dr. Jur. Jan Schmidt-Brand has been the Chief Financial Officer of Wilex AG since September 01, 2012 and serves as its Member of The Executive Management Board and Chief Executive Officer. Dr. Jur. Schmidt...

CEO Compensation Analysis

Compensation vs Market: Jan's total compensation ($USD506.90K) is about average for companies of similar size in the German market ($USD670.79K).

Compensation vs Earnings: Jan's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: HPHA's management team is considered experienced (3.5 years average tenure).

Board Members

Experienced Board: HPHA's board of directors are seasoned and experienced ( 12 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/23 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2022/02/28
Annual Earnings	2021/11/30